In a short period of time, this immunotherapy biotech could either become a multi-bagger or trade near $0.
News & Analysis: Northwest Biotherapeutics
Will a 14-year clinical trial evaluating an immunotherapy for the most lethal form of brain cancer have a positive outcome?
Even though the market kept climbing Wednesday, these three stocks couldn't keep up. Find out why.
If you want to do well in the markets, it helps to know which stocks you shouldn't buy.
If you want to beat the market, start by knowing which stocks you shouldn't buy.
News of a phase 3 trial halt for the company's lead compound DCVax-L send investors running.
MannKind and Northwest Biotherapeutics have attracted ginormous short positions this year. Is the Street wrong about these stocks?
Could this illegal drug unlock the secret to fighting brain cancer? A recently released study by a group of London researchers would suggest so.
Northwest Biotherapeutics stock has soared this year on the heels of three catalysts. Find out what those catalysts are and whether or not NW Bio still has legs.
Five clinical updates that made waves in the biotech sector this week, as well as the surprising buyout that still has Wall Street abuzz.